Abstract
Objectives: Disease severity, previous medications and immunosuppressive agents could affect the antibody response against SARS-CoV-2. This study aimed to analyze variables affecting the humoral response to SARS-CoV-2.
Methods: This prospective cohort study included adult patients who recovered from COVID-19 and were admitted to a COVID-19 follow-up unit. Eight patient groups were defined in accordance with the results of thoracic computed tomography (CT), SARS-CoV-2 PCR test, and tocilizumab or anakinra use during active disease. Anti-S IgG antibodies were determined by ELISA in serum samples. Anti-S positive and negative cases were compared.
Results: A total of 518 patients were included in the study. SARS-CoV-2 IgG antibodies were positive in 82.8% of patients. SARS-CoV-2 PCR positivity, extent of lung involvement on CT, and time to antibody testing were independently associated with antibody positivity. Tocilizumab, anakinra or prednisolone use was not a factor affecting the antibody response. The rate of antibody response and sample/CO values among antibody-positive patients showed a linear relationship with the extent of lung involvement on CT.
Conclusions: The use of tocilizumab, anakinra and prednisolone for COVID-19 did not affect the antibody response against SARS-CoV-2. The main driver of antibody response among patients with COVID-19 was the extent of pulmonary involvement on CT.
Keywords: Anakinra; Antibody; Prednisolone; SARS-CoV-2; Tocilizumab.
【저자키워드】 SARS-CoV-2, Anakinra, Tocilizumab, antibody, Prednisolone, 【초록키워드】 COVID-19, Antibody testing, Tocilizumab, severity, lung involvement, Antibody Response, prospective cohort study, ELISA, Computed tomography, IgG antibody, SARS-CoV-2 IgG antibody, Patient, Follow-up, medication, patients, Active disease, SARS-CoV-2 PCR, Thoracic, humoral, serum samples, pulmonary involvement, linear relationship, positive, SARS-CoV-2 PCR test, variable, Affect, defined, patient group, not affect, affecting, the antibody response, immunosuppressive agent, patients with COVID-19, 【제목키워드】 Tocilizumab, Antibody Response, prospective cohort study, Patient, Analysis, Prednisolone, Factor, affecting, the antibody response,